Research programme: decoy oligonucleotide therapeutics - AnGes MG

Drug Profile

Research programme: decoy oligonucleotide therapeutics - AnGes MG

Alternative Names: NF-kappa-B/E2F decoy oligonucleotide; NF-kappa-B/Ets decoy oligonucleotide

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnGes MG
  • Developer AnGes MG; Osaka University
  • Class Oligonucleotides
  • Mechanism of Action E2F transcription factor inhibitors; Matrix metalloproteinase inhibitors; NF-kappa B inhibitors; Proto-oncogene-protein-c-ets inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Vascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in Japan (Parenteral)
  • 30 Nov 2011 Pharmacodynamics data from a preclinical study in Vascular disorders released by AnGes MG
  • 17 Nov 2008 Preclinical trials in Vascular disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top